HuidaGene and Synthego Enter into Licensing Agreement for Next-Generation Gene-Editing Nuclease hfCas12Max®

May 30, 2024 08:37 CST Updated 08:37

Synthego

Gene Engineering Solutions Provider

On May 29, 2024, Hui-Gene Therapeutics and Synthego jointly announced,Both parties discussed the high-fidelity nuclease hfCas12Max^®Reached a licensing cooperationHui-Gene Therapeutics is a global biotechnology company at the clinical stage, focusing on the development of CRISPR gene therapy drugs. Synthego is an industry leader providing innovative solutions for genetic engineering. This collaboration not only demonstrates Hui-Gene Therapeutics' hfCas12Max^®The important clinical application potential also reflects Synthego's continued focus on advanced GMP manufacturing capabilities. According to the undisclosed financial terms of the licensing agreement, Hui-Gene Therapeutics will grant Synthego ownership of hfCas12Max.^®The Rights to Nuclease Production and Commercial Sales, OptimizedgRNA for Research UseThe rights, as well as hfCas12Max^®Sublicense rights for therapeutic use of nucleases.

This important collaboration will streamline the development process of CRISPR-based therapeutic applications, providing developers with high-precision, high-efficiency, and next-generation genome editing tools to enhance the development efficiency of CRISPR therapies.Dr. Yao Xuan, Co-founder and President of Hui-Gene Therapeutics"Hui-Gene Therapeutics, as one of the global leaders in gene editing technology and therapy, possesses independently developed CRISPR gene editing technology and has made deep product layouts in the neurological and ophthalmic fields. In the future, together with our partner Synthego, we will jointly promote research and new drug development in the CRISPR gene therapy field, accelerating the provision of transformative gene therapies for patients worldwide."

Synthego CEO Craig ChristiansonRegarding the enthusiasm for the collaboration with Hui-Gene Therapeutics' hfCas12Max: "The combination of our advanced CRISPR GMP manufacturing capabilities and regulatory expertise with Hui-Gene Therapeutics' next-generation nuclease technology is a crucial step in advancing transformative therapies in the cell and gene therapy field. This collaboration highlights Synthego's commitment to CRISPR therapeutics, as we focus on GMP manufacturing and CRISPR."Comprehensive solutions to support therapy development. This collaboration willhfCas12Max^®"Integrating into our CRISPR toolkit, it aligns perfectly with our original intention and aspiration to improve the accessibility and efficiency of gene editing tools."

hfCas12Max^®It is Hui-Gene TherapeuticsRelying on HG-PRECISE^®Technology Platform,Independently Developed and Optimized New DNA Editing System: hfCas12Max^®Demonstrates superior on-target editing efficiency and lower off-target activity in mammalian cells, with the size advantage of being deliverable by a single AAV package. hfCas12Max^®The commercialization will significantly improve the accessibility of the CRISPR gene editing system, provide greater operational flexibility, and promote CRISPR-basedDevelopment of Cell and Gene Therapy.

This collaboration solidifies the two companies' positions as catalysts for innovation, advancing their shared mission.——Transform genomic medicine and achieve unprecedented therapeutic outcomes.

AboutHui-Gene Therapeutics

Hui-Gene Therapeutics utilizes its proprietary HG-PRECISE^®Platform to discover, design, and develop new CRISPR gene therapies. Clinical-stage programs currently being advanced by the company include HG004 for treatment.RPE65Mutation-Associated Inherited Retinal Diseases (Granted FDA ODD and RPDD Dual Designation），HG202（RNA Editing Therapy) for the treatment of neovascular age-related macular degeneration (nAMD), and preclinical gene editing pipeline, including HG204 (RNA Editing Therapy) TreatmentMECP2Recurrent Syndrome (MDS） (Granted with both U.S. ODD and RPDD designations, and European ODD designation）、HG302（DNA Editing Therapy) Treatment of Duchenne Muscular Dystrophy (DMD）(Granted Dual Designation of ODD and RPDD), and HG303 (DNA Editing Therapy) Treatment of Amyotrophic Lateral Sclerosis (ALS), among other projects. Hui-Gene Therapeutics boasts a rich and in-depth intellectual property portfolio and is emerging as a leader in the field of neurology and ophthalmology gene therapy.

AboutSynthego

Synthego is a leading provider of genomic engineering solutions, offering a comprehensive suite of products and services to accelerate the development of CRISPR-based cell and gene therapies. Synthego is committed to supporting researchers and innovators, driving advancements from preclinical to clinical applications with its cutting-edge CRISPR technology and expertise.

E.N.D

Previous article recommendations:

FDA Releases Draft Guidance on Platform Technology for Drug Development to Expedite Approval of Cell and Gene Therapies

CAR-T Therapy Enters a New Realm: Tsinghua University's Peng Min Team Develops Novel CAR-T Cells, One Injection to Prevent Recurrent Allergic Asthma

World's First! Peking Union Medical College Hospital Publishes Phase 1 Study Results on Nasal Mucosal Route Transplantation of Neural Stem Cells for Parkinson's Disease Treatment

Hefei Releases New Policy to Promote High-Quality Development of the Biomanufacturing Industry, Focusing on Directions Such as Synthetic Biology and Gene Editing Technology

Enkaice Pharmaceutical's Universal NK Approved for Clinical Trials, Targeting Solid Tumors

China's First In Vivo Gene Editing Product to Enter IIT Clinical Study, ART001 by Rayzene Gene, to Release Latest 24-Week Clinical Study Data

Ling Shi Zhi Yuan Completes Angel Round Financing

Are leading Chinese CXOs like Wuxi AppTec beginning to shift their focus?

Next Breakthrough: Application of mRNA Technology in Influenza, RSV, and Cancer Vaccines

Beijing: Deploying "Nuclear Explosion Point" Special Projects in Cutting-edge Technology Fields such as Cell Gene Therapy and Synthetic Biology

Boosting the Gene Editing Efficiency of This Cas9 a Hundredfold! Nobel Team's Heavyweight Cell Paper Discovers a Universal Strategy to Improve Gene Editing Activity

1.2 Billion: Pudong Establishes Two Life Science Industry and Park Service Companies to Boost Biomedical Industry Investment and Incubation Acceleration!

Chongqing Issues New Policy to Encourage Foreign-Invested Enterprises to Legally Conduct Clinical Trials in Chongqing for Overseas Market-Authorized Cell and Gene Therapy Drugs

STAR Market Welcomes a "Genuinely Red" CRO Company

Application of Micro/Nano Electroporation Technology in Gene Therapy

Pharmaron Sells Equity Stake in Participating Company to Johnson & Johnson for $102 Million

Shanghai Advanced Research Institute Achieves Breakthrough Progress in AI Prediction of Lipid Nanoparticles (LNPs) for mRNA Drug Delivery Systems

Breaks Through the Blood-Brain Barrier, More Effective Than AAV9: Chinese Scholar's First-Author Science Paper Develops New AAV Vector

AAV Gene Therapy Research Achievements of Kanghong Pharmaceutical Published in Nature Sub-Journal: A Novel AAV Vector Enables Efficient, Cross-Species Ocular Targeted Gene Delivery

People's Daily: Cell Therapy Pushes the Treatment of Difficult and Severe Diseases into a New Stage!

40:1 Disparity! The US House of Representatives' New Biosecurity Bill Passes Hearing

First in China! This Province Issues Document, Listing "Gene and Cell Therapy Source Engineering, Strengthening the Development of Gene Editing, Immunotherapy and Other Technologies and Products" as Key New Quality Productivity Cultivation NMPA Leadership Investigates Progress in Cell and Gene Therapy Product Development; Over 400 Cell and Gene Therapy Products Are Undergoing Clinical Drug Trials in China

Cancer-Free for the 12th Year! Emily, the World's First Girl Cured by CAR-T Therapy, Updates Her Status as Scheduled

Guangdong Provincial Health Commission Takes the Lead in Establishing China's First Quality Control Center for Clinical Research on Dry (Somatic) Cells

Synthego Completes First-in-China Phase I Clinical Dosing of Lentiviral Vector Gene Therapy for Thalassemia in Collaboration with Ruijin Hospital

Changes in the U.S. Biosecurity Act

The First Yikaiyada® CAR-T Cell Treatment Center in the Macao Region Settles at Kiang Wu Hospital

Central China's First CAR-T Cell Immunotherapy Clinic Launched

Frontier Technology Series: Research on Drug Delivery Technology

Statement: The content is sourced from the official Hui-Gene Therapeutics, this article aimsIn knowledge sharing, all content is for reference only and does not constitute any advice.